Literature DB >> 22968304

Virtual screening for LPA2-specific agonists identifies a nonlipid compound with antiapoptotic actions.

Gyöngyi N Kiss1, James I Fells, Renuka Gupte, Sue-Chin Lee, Jianxiong Liu, Nóra Nusser, Keng G Lim, Ramesh M Ray, Fang-Tsyr Lin, Abby L Parrill, Balázs Sümegi, Duane D Miller, Gabor Tigyi.   

Abstract

Lysophosphatidic acid (LPA) is a highly potent endogenous lipid mediator that protects and rescues cells from programmed cell death. Earlier work identified the LPA₂ G protein-coupled receptor subtype as an important molecular target of LPA mediating antiapoptotic signaling. Here we describe the results of a virtual screen using single-reference similarity searching that yielded compounds 2-((9-oxo-9H-fluoren-2-yl)carbamoyl)benzoic acid (NSC12404), 2-((3-(1,3-dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)propyl)thio)benzoic acid (GRI977143), 4,5-dichloro-2-((9-oxo-9H-fluoren-2-yl)carbamoyl)benzoic acid (H2L5547924), and 2-((9,10-dioxo-9,10-dihydroanthracen-2-yl)carbamoyl) benzoic acid (H2L5828102), novel nonlipid and drug-like compounds that are specific for the LPA₂ receptor subtype. We characterized the antiapoptotic action of one of these compounds, GRI977143, which was effective in reducing activation of caspases 3, 7, 8, and 9 and inhibited poly(ADP-ribose)polymerase 1 cleavage and DNA fragmentation in different extrinsic and intrinsic models of apoptosis in vitro. Furthermore, GRI977143 promoted carcinoma cell invasion of human umbilical vein endothelial cell monolayers and fibroblast proliferation. The antiapoptotic cellular signaling responses were present selectively in mouse embryonic fibroblast cells derived from LPA(1&2) double-knockout mice reconstituted with the LPA₂ receptor and were absent in vector-transduced control cells. GRI977143 was an effective stimulator of extracellular signal-regulated kinase 1/2 activation and promoted the assembly of a macromolecular signaling complex consisting of LPA₂, Na⁺ - H⁺ exchange regulatory factor 2, and thyroid receptor interacting protein 6, which has been shown previously to be a required step in LPA-induced antiapoptotic signaling. The present findings indicate that nonlipid LPA₂-specific agonists represent an excellent starting point for development of lead compounds with potential therapeutic utility for preventing the programmed cell death involved in many types of degenerative and inflammatory diseases.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22968304      PMCID: PMC3502618          DOI: 10.1124/mol.112.079699

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  43 in total

1.  Chris Lipinski discusses life and chemistry after the Rule of Five.

Authors:  Christopher A Lipinski
Journal:  Drug Discov Today       Date:  2003-01-01       Impact factor: 7.851

2.  Overexpression of edg-2/vzg-1 induces apoptosis and anoikis in ovarian cancer cells in a lysophosphatidic acid-independent manner.

Authors:  T Furui; R LaPushin; M Mao; H Khan; S R Watt; M A Watt; Y Lu; X Fang; S Tsutsui; Z H Siddik; R C Bast; G B Mills
Journal:  Clin Cancer Res       Date:  1999-12       Impact factor: 12.531

3.  Identification of residues responsible for ligand recognition and regioisomeric selectivity of lysophosphatidic acid receptors expressed in mammalian cells.

Authors:  Yuko Fujiwara; Vineet Sardar; Akira Tokumura; Daniel Baker; Kimiko Murakami-Murofushi; Abby Parrill; Gabor Tigyi
Journal:  J Biol Chem       Date:  2005-08-22       Impact factor: 5.157

4.  LPA protects intestinal epithelial cells from apoptosis by inhibiting the mitochondrial pathway.

Authors:  Wenlin Deng; De-An Wang; Elvira Gosmanova; Leonard R Johnson; Gabor Tigyi
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2003-05       Impact factor: 4.052

5.  Short-chain phosphatidates are subtype-selective antagonists of lysophosphatidic acid receptors.

Authors:  D J Fischer; N Nusser; T Virag; K Yokoyama; D L Baker; D Bautista; A L Parrill; G Tigyi
Journal:  Mol Pharmacol       Date:  2001-10       Impact factor: 4.436

6.  Hepatoma cell migration through a mesothelial cell monolayer is inhibited by cyclic AMP-elevating agents via a Rho-dependent pathway.

Authors:  M Mukai; H Nakamura; M Tatsuta; T Iwasaki; A Togawa; F Imamura; H Akedo
Journal:  FEBS Lett       Date:  2000-11-03       Impact factor: 4.124

7.  A single amino acid determines lysophospholipid specificity of the S1P1 (EDG1) and LPA1 (EDG2) phospholipid growth factor receptors.

Authors:  D A Wang; Z Lorincz; D L Bautista; K Liliom; G Tigyi; A L Parrill
Journal:  J Biol Chem       Date:  2001-10-16       Impact factor: 5.157

8.  Cyclic phosphatidic acid inhibits RhoA-mediated autophosphorylation of FAK at Tyr-397 and subsequent tumor-cell invasion.

Authors:  Mutsuko Mukai; Teruo Iwasaki; Masaharu Tatsuta; Atsushi Togawa; Hiroyuki Nakamura; Kimiko Murakami-Murofushi; Susumu Kobayashi; Fumio Imamura; Masahiro Inoue
Journal:  Int J Oncol       Date:  2003-06       Impact factor: 5.650

9.  Lysophosphatidic acid protects and rescues intestinal epithelial cells from radiation- and chemotherapy-induced apoptosis.

Authors:  Wenlin Deng; Louisa Balazs; De-An Wang; Lester Van Middlesworth; Gabor Tigyi; Leonard R Johnson
Journal:  Gastroenterology       Date:  2002-07       Impact factor: 22.682

Review 10.  Molecular basis for lysophosphatidic acid receptor antagonist selectivity.

Authors:  Vineet M Sardar; Debra L Bautista; David J Fischer; Kazuaki Yokoyama; Nora Nusser; Tamas Virag; De-an Wang; Daniel L Baker; Gabor Tigyi; Abby L Parrill
Journal:  Biochim Biophys Acta       Date:  2002-05-23
View more
  18 in total

1.  Lysophosphatidic acid inhibits CD8 T cell activation and control of tumor progression.

Authors:  Shannon K Oda; Pamela Strauch; Yuko Fujiwara; Amin Al-Shami; Tamas Oravecz; Gabor Tigyi; Roberta Pelanda; Raul M Torres
Journal:  Cancer Immunol Res       Date:  2013-10       Impact factor: 11.151

Review 2.  Lysophosphatidic Acid and Sphingosine-1-Phosphate: A Concise Review of Biological Function and Applications for Tissue Engineering.

Authors:  Bernard Y K Binder; Priscilla A Williams; Eduardo A Silva; J Kent Leach
Journal:  Tissue Eng Part B Rev       Date:  2015-07-14       Impact factor: 6.389

3.  The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

4.  The LPA2 receptor agonist Radioprotectin-1 spares Lgr5-positive intestinal stem cells from radiation injury in murine enteroids.

Authors:  Bryan Kuo; Erzsébet Szabó; Sue Chin Lee; Andrea Balogh; Derek Norman; Asuka Inoue; Yuki Ono; Junken Aoki; Gábor Tigyi
Journal:  Cell Signal       Date:  2018-07-29       Impact factor: 4.315

Review 5.  Lysophosphatidic acid type 2 receptor agonists in targeted drug development offer broad therapeutic potential.

Authors:  Gabor J Tigyi; Leonard R Johnson; Sue Chin Lee; Derek D Norman; Erzsebet Szabo; Andrea Balogh; Karin Thompson; Alyssa Boler; W Shannon McCool
Journal:  J Lipid Res       Date:  2019-01-28       Impact factor: 5.922

6.  The autotaxin-LPA2 GPCR axis is modulated by γ-irradiation and facilitates DNA damage repair.

Authors:  Andrea Balogh; Yoshibumi Shimizu; Sue Chin Lee; Derek D Norman; Ruchika Gangwar; Mitul Bavaria; ChangSuk Moon; Pradeep Shukla; Radakrishna Rao; Ramesh Ray; Anjaparavanda P Naren; Souvik Banerjee; Souvik Banerje; Duane D Miller; Louisa Balazs; Louis Pelus; Gabor Tigyi
Journal:  Cell Signal       Date:  2015-05-28       Impact factor: 4.315

7.  Discovery and synthetic optimization of a novel scaffold for hydrophobic tunnel-targeted autotaxin inhibition.

Authors:  Lauren E Ragle; Dilip J Palanisamy; Margaux J Joe; Rachel S Stein; Derek D Norman; Gabor Tigyi; Daniel L Baker; Abby L Parrill
Journal:  Bioorg Med Chem       Date:  2016-08-04       Impact factor: 3.641

8.  Mitigation of radiation injury by selective stimulation of the LPA(2) receptor.

Authors:  Gyöngyi N Kiss; Sue-Chin Lee; James I Fells; Jianxiong Liu; William J Valentine; Yuko Fujiwara; Karin Emmons Thompson; Charles R Yates; Balázs Sümegi; Gabor Tigyi
Journal:  Biochim Biophys Acta       Date:  2013-01

9.  Lysophosphatidic acid receptor 5 inhibits B cell antigen receptor signaling and antibody response.

Authors:  Jiancheng Hu; Shannon K Oda; Kristin Shotts; Erin E Donovan; Pamela Strauch; Lindsey M Pujanauski; Francisco Victorino; Amin Al-Shami; Yuko Fujiwara; Gabor Tigyi; Tamas Oravecz; Roberta Pelanda; Raul M Torres
Journal:  J Immunol       Date:  2014-06-02       Impact factor: 5.422

Review 10.  Molecular mechanisms of target recognition by lipid GPCRs: relevance for cancer.

Authors:  M T M van Jaarsveld; J M Houthuijzen; E E Voest
Journal:  Oncogene       Date:  2015-12-07       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.